List view / Grid view
22 September 2014 | By Kymab
Kymab Limited announced that the European Patent Office has granted Kymab's request to entirely revoke European Patent EP1,360,287B1, owned by Regeneron Pharmaceuticals Inc...
22 September 2014 | By Andrew Lloyd & Associates
GENTICEL announces that following the Supervisory Board’s meeting held on September 11, 2014, Mary Tanner has been appointed to the board as a new independently-acting member and as Audit Committee chairman...
22 September 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia and follicular lymphoma...
19 September 2014 | By Nexstim
Nexstim Oy announces its intention to proceed with an Initial Public Offering of Nexstim on NASDAQ OMX First North Finland and NASDAQ OMX First North Sweden...
19 September 2014 | By Novo Nordisk
New analyses of Phase 3a IDegLira (insulin degludec /liraglutide; Xultophy®) DUAL™ study data show an early and substantial improvement in glycaemic control, and a beneficial weight profile in type 2 diabetes patients compared to insulin degludec...
19 September 2014 | By Andrew Lloyd & Associates
Bioxodes SA announces that it has successfully brought its lead product, Ir-CPI, through pre-clinical development confirming its potential as the first in a new class of antithrombotic medicines...
19 September 2014 | By BIogen Idec
Biogen Idec announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY™ (peginterferon beta-1a) were maintained in adults with relapsing-remitting multiple sclerosis (RRMS) beyond the first year of the study...
18 September 2014 | By kdm communications
Tecan has launched the Freedom EVO® NGS workstation to simplify next-generation sequencing (NGS) sample preparation and PCR set-up...
18 September 2014 | By Biogen Idec
Biogen Idec and AbbVie announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA™ (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity...
18 September 2014 | By Cubist Pharmaceuticals
With resistant bacterial infections resulting in an estimated 25,000 deaths in the European Union and 23,000 deaths in the United States annually, the issues of rising antibiotic resistance and the lack of treatment options have raised alarms with world leaders...
18 September 2014 | By Issued by Hume Brophy on behalf of Ergomed
Good progress with partnerships and additional clinical studies commenced...
18 September 2014 | By Merck
MSD, known as Merck & Co., Inc. in the United States and Canada, announced the presentation of the first data from the Phase 3 clinical development programme for omarigliptin, MSD’s investigational treatment for type 2 diabetes...
18 September 2014 | By Globaldata
Despite numerous product launches in the metastatic castration-resistant prostate cancer treatment market since 2010, ample opportunity still exists for drug developers to claim their stake in the arena...
18 September 2014 | By Roche
Roche announced that it is planning to invest more than half a billion Swiss francs in buildings and infrastructure projects at Kaiseraugst...
17 September 2014 | By PDS
PDS announces that a top 5 pharma company has used TranSEND™ to successfully submit multiple SEND datasets derived from different data sources to the Food and Drug Administration...
